Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Mastercard ...

US researchers have found that obesity or being overweight is linked to a life-threatening heart condition that alters muscle structure in the organ ... Mounjaro And Zepbound Can Reduce Risks Of Heart ...

Muscle-sparing is particularly important in patients with heart failure as it is associated with higher mortality.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity ...

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Paying $1,200 a month for the name-brand drug Zepbound wasn’t sustainable, and it was becoming impossible to find, she said. And she’s not alone. Readdy turned to online communities where ...

Compounding pharmacies have used a legal provision that allows them to make knockoff versions of Lilly’s Zepbound and Mounjaro while they are in a shortage. While Lilly has raised questions ...

Most U.S. patients are covered by health insurance and would likely pay less for the drugs. Novo and rival Eli Lilly, which makes the weight-loss drug Zepbound, have filed a flurry of lawsuits against ...